Dapagliflozin

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Focal Segmental Glomerulosclerosis

Conditions

Focal Segmental Glomerulosclerosis

Trial Timeline

Sep 1, 2015 → Apr 24, 2017

NCT ID

NCT02585804

About Dapagliflozin

Dapagliflozin is a approved stage product being developed by AstraZeneca for Focal Segmental Glomerulosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02585804. Target conditions include Focal Segmental Glomerulosclerosis.

What happened to similar drugs?

3 of 9 similar drugs in Focal Segmental Glomerulosclerosis were approved

Approved (3) Terminated (1) Active (6)

✅OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved

✅Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, ZonisamidePfizerApproved

✅Levetiracetam + Carbamazepine + LamotrigineUCBApproved

🔄Empasiprubart + IVIG (Intravenous Immunoglobulin)ArgenxPhase 3

🔄Gadoxetic Acid Disodium (Primovist, BAY86-4873)BayerPhase 3

🔄XEN1101 + PlaceboXenon PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (16)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06610526	Approved	Active	Aug 23, 2024	May 31, 2027	Chronic Kidney Disease
NCT05250011	Pre-clinical	Completed	Apr 19, 2022	Apr 15, 2024	Heart Failure, Reduced Ejection Fraction
NCT03877237	Phase 3	Completed	Apr 9, 2019	Mar 7, 2020	Heart Failure With Reduced Ejection Fraction (HFrEF)
NCT03877224	Phase 3	Completed	Apr 4, 2019	Jul 9, 2020	Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT03782259	Approved	Completed	Feb 26, 2019	Nov 16, 2022	Type 2 Diabetes Mellitus
NCT03338855	Approved	Completed	Mar 5, 2018	Nov 4, 2019	Diabetes Mellitus, Type 2
NCT03152084	Approved	Terminated	Jul 12, 2017	Mar 20, 2020	Diabetes Mellitus, Type 2
NCT02585804	Approved	Completed	Sep 1, 2015	Apr 24, 2017	Focal Segmental Glomerulosclerosis
NCT02460978	Phase 3	Completed	Jul 8, 2015	Apr 18, 2018	Type 1 Diabetes Mellitus
NCT02420392	Pre-clinical	Completed	Feb 1, 2015	Apr 1, 2016	Diabetes Mellitus, Type 2
NCT01294436	Phase 3	Completed	Feb 1, 2011	Sep 1, 2012	Type2 Diabetes
NCT01165268	Phase 1	Completed	Aug 1, 2010	Dec 1, 2010	Type 2 Diabetes Mellitus
NCT01055652	Phase 1	Completed	Jan 1, 2010	Apr 1, 2010	Type 2 Diabetes Mellitus
NCT00908271	Phase 1	Completed	Jul 1, 2009	Aug 1, 2009	Type 2 Diabetes Mellitus
NCT00726505	Phase 1	Terminated	Jun 1, 2009	Aug 1, 2009	Diabetes, NOS
NCT00554450	Phase 1	Completed	Mar 1, 2006	Oct 1, 2008	Diabetes Mellitus, Type 2

Competing Products

20 competing products in Focal Segmental Glomerulosclerosis

See all competitors

Product	Company	Stage	Hype Score
OnabotulinumtoxinA 145 UNT [Botox]	AbbVie	Approved	35
Enfuvirtide + Tenofovir-Emtricitabine	Roche	Phase 2	35
CCX140-B	Amgen	Phase 2	27
PF-06730512	Pfizer	Phase 2	27
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide	Pfizer	Approved	43
VX-147	Vertex Pharmaceuticals	Phase 2	35
VX-147	Vertex Pharmaceuticals	Phase 1	29
IXP	Vertex Pharmaceuticals	Phase 1	29
fresolimumab + fresolimumab + Placebo	Sanofi	Phase 2	35
GC1008 + GC1008 + GC1008 + GC1008	Sanofi	Phase 1	29
frexalimab + brivekimig + rilzabrutinib + placebo	Sanofi	Phase 2	42
Vivaglobin	CSL	Phase 2	35
UCB0942	UCB	Phase 2	27
Levetiracetam + Carbamazepine + Lamotrigine	UCB	Approved	43
Brivaracetam + Brivaracetam	UCB	Phase 2	35
Lacosamide	UCB	Phase 2	27
UCB0942 + UCB0942 + Placebo	UCB	Phase 2	35
Lacosamide	UCB	Pre-clinical	26
ARGX-117	Argenx	Phase 2	36
Empasiprubart + IVIG (Intravenous Immunoglobulin)	Argenx	Phase 3	44